Literature DB >> 3142542

Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.

A R Morton1, J A Cantrill, G V Pillai, A McMahon, D C Anderson, A Howell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3142542      PMCID： PMC1834406          DOI： 10.1136/bmj.297.6651.772

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells.

Authors:  J Pfeilschifter; S M D'Souza; G R Mundy
Journal:  Endocrinology       Date:  1987-07       Impact factor: 4.736

2.  Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.

Authors:  A T van Holten-Verzantvoort; O L Bijvoet; F J Cleton; J Hermans; H M Kroon; H I Harinck; P Vermey; J W Elte; J P Neijt; L V Beex
Journal:  Lancet       Date:  1987-10-31       Impact factor: 79.321

3.  Human recombinant transforming growth factor alpha stimulates bone resorption and inhibits formation in vitro.

Authors:  K J Ibbotson; J Harrod; M Gowen; S D'Souza; D D Smith; M E Winkler; R Derynck; G R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

4.  Value of CA 15:3 in the follow-up of breast cancer patients.

Authors:  D M Pons-Anicet; B P Krebs; R Mira; M Namer
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640
  4 in total
  21 in total

1.  Treating bony metastases.

Authors:  D Dodwell; A Howell
Journal:  BMJ       Date:  1991-08-24

2.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

3.  Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice.

Authors:  M E Stearns; M Wang
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

Review 4.  Causes and treatment of bone pain of malignant origin.

Authors:  B Thürlimann; N D de Stoutz
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

5.  Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.

Authors:  M E Stearns
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

6.  Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site.

Authors:  M Tanaka; H Fushimi; T Fuji; J M Ford
Journal:  Eur Spine J       Date:  1996       Impact factor: 3.134

Review 7.  Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research.

Authors:  J J Body
Journal:  Support Care Cancer       Date:  1993-01       Impact factor: 3.603

Review 8.  Postmenopausal breast cancer. Drug therapy in the 1990s.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

Review 9.  Bisphosphonate treatment of lytic bone metastases.

Authors:  A Lipton; J R Berenson
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

10.  Breast tumour stroma is a prognostic indicator and target for therapy.

Authors:  Anthony Howell; Goran Landberg; Jonas Bergh
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.